Pfizer to Acquire Excaliard Pharmaceuticals
Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.
Up in Smoke
In life, expect the unexpected. In science, expect the unexpected.